サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1247466

In Situハイブリダイゼーション(ISH)の世界市場-2023-2030

Global In Situ Hybridization Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
In Situハイブリダイゼーション(ISH)の世界市場-2023-2030
出版日: 2023年03月28日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

In Situ Hybridizationの世界市場は、2022年に97億40万米ドルに達し、2030年には150億8,746万米ドルに達すると予測されます。同市場は予測期間（2023-2030年）に11.9%のCAGRで成長しています。

In situハイブリダイゼーション（ISH）は、標識された相補的DNA、RNA、または修飾核酸鎖（すなわちプローブ）を使用して、特定のDNAまたはRNA配列を組織の一部またはセクション、または組織が十分に小さい場合は組織全体（例えば、植物の種子、ショウジョウバエ胚）、細胞、および循環腫瘍細胞（CTC）内に局在化します。組織切片にタンパク質を局在させることが多い免疫組織化学は、これとは異なるものです。

市場力学

増加するがん患者数

喫煙や食生活の乱れが、がんの発生を増加させる原因となっています。これがISH市場の大きな成長要因となっています。例えば、WHOの報告によると、2020年にはがんが世界の死亡原因のトップになり、約1,000万人、つまり約6人に1人の割合で死亡することになるとされています。乳がん、肺がん、結腸がん、直腸がん、前立腺がんなどが最も多いがんの種類です。タバコの使用、肥満度の高さ、飲酒、野菜や果物の少ない食事、運動不足は、がんによる死亡の約3分の1を占めています。

低・中所得国では、ヒトパピローマウイルス（HPV）や肝炎などのがんを引き起こす感染症が、がん患者の30％の原因になっていると考えられています。その結果、in-situ hybridizationの需要は予測される期間中に増加します。

訓練された人材の不足が市場の妨げになります。

ISHベースの検査を実施するためには、染色体や遺伝子の分子的な仕様に精通している必要があります。手動から自動化への移行に対する抵抗も、業界成長の妨げとなります。多くのサプライヤーが、手作業や時代遅れのプロセスからITベースのプロセスへの移行は、不可能ではないにせよ、困難なことなのです。このため、ISHベースの診断の広範な使用は、特に発展途上国では、資格を持ち、教育を受け、技術的に優れた検査担当者の不足によって制限されています。

目次

第1章 調査手法とスコープ

  • 調査手法
  • 調査目的および調査範囲について

第2章 定義と概要

第3章 エグゼクティブサマリー

  • タイプ別スニペット
  • アプリケーション別スニペット
  • エンドユーザー別スニペット
  • 地域別スニペット

第4章 ダイナミックス

  • インパクトのあるファクター
    • 促進要因
      • がん罹患率の増加
      • コンパニオン診断薬に関する認知度
    • 抑制要因
      • 訓練された人材の不足が市場の妨げになる
    • 機会
    • 影響度分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格アナリシス
  • レギュラトリー・アナリシス
  • アンメットニーズ
  • パイプラインの解析

第6章 COVID-19の分析

  • COVID-19の解析について
    • COVID-19シナリオ前
    • 現在のCOVID-19シナリオ
    • ポストCOVID-19または未来シナリオ
  • COVIDの中での価格ダイナミクス-19
  • 需給スペクトル
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的な取り組み
  • 結論

第7章 製品別

  • 消耗品
  • 楽器
  • ソフトウェア

第8章 テクノロジー別

  • フィッシュ
    • DNA FISH
    • RNA FISH
    • PNA FISH
  • シシュ

第9章 アプリケーション別

  • がん診断薬
  • 細胞診
  • 感染症診断薬
  • ニューロサイエンス
  • 免疫学

第10章 エンドユーザー別

  • 病院・診断薬研究所
  • 学術・研究機関など
  • 製薬会社・バイオテクノロジー企業
  • 受託研究機関

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • ロシア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第12章 競合情勢

  • 競合シナリオ
  • 市況分析・シェア分析
  • M&A分析

第13章 企業プロファイル

  • Abbott Laboratories
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な展開
  • F. Hoffmann-La Roche Ag.
  • Becton, Dickinson And Company
  • Agilent Technologies, Inc.
  • Thermo Fisher Scientific
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Creative Bioarray
  • Biocat Gmbh
  • Zytovision.

第14章 付録

目次
Product Code: BT3183

Market Overview

The global In Situ Hybridization market reached US$ 9700.40 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 15087.46 million by 2030. The market is growing at a CAGR of 11.9% during the forecast period (2023-2030).

In situ hybridization (ISH) uses a labeled complementary DNA, RNA, or modified nucleic acid strand (i.e., probe) to localize a particular DNA or RNA sequence in a portion or section of tissue, or if the tissue is small enough, in the entire tissue (e.g., plant seeds, Drosophila embryos), in cells, and in circulating tumor cells (CTCs). Immunohistochemistry, which often localizes proteins in tissue slices, is different from this.

Market Dynamics

The Increasing incidence of Cancer cases

Smoking and poor eating habits are to responsible for the increase in cancer occurrences. That is a significant growth factor for the ISH market. For instance, the WHO reports that cancer will be the top cause of mortality globally in 2020, accounting for around 10 million deaths, or roughly one in every six. Breast, lung, colon, rectum, and prostate cancers are the most prevalent types of cancer. The use of tobacco, having a high body mass index, drinking alcohol, eating few fruits and vegetables, and not exercising account for about one-third of cancer-related fatalities.

In low- and lower-middle-income nations, cancer-causing infections including the human papillomavirus (HPV) and hepatitis are thought to be the cause of 30% of cancer cases. And as a result, in-situ hybridization demand is increasing during the anticipated period.

The Lack of trained personnel will hamper the market.

To carry out an ISH-based test, one needs to be aware of the molecular specifics of a chromosome or gene. Resistance to the transition from manual to automated procedures is another barrier to the industry's growth. Too many suppliers, making the transfer from manual or antiquated processes to IT-based ones is challenging, if not impossible. Because of this, the broad use of ISH-based diagnosis is limited, particularly in developing countries, by a lack of qualified, educated, and technically adept laboratory personnel.

Segment Analysis

The global In Situ Hybridization market is segmented based on product, technology, application, end user,and region.

On basis of the technology, FISH isexpected to hold the largest share

The FISH segment is expected to hold the largest share in the In Situ Hybridization market owing to the increasing number oforthopedic surgeries across the globe. For instance, a chromosome from a person is attached to a glass slide using the Fluorescence In Situ Hybridization (FISH) laboratory procedure, which exposes the chromosome to a probe made of purified DNA that has been fluorescently dyed. It is used to diagnose cancer, chromosomal abnormalities, gene mapping, and genetic illnesses. Growing genetic problems, chronic diseases, and rising demand for effective diagnostic methods are factors in the expansion of the FISH segment. And when more products are released by different market players, the market expands as a result of the rising demand for FISH methods.

For instance, in May 2021, as a part of its newly launched Vizgen release program, Vizgen launched its publicly accessible data collection. The precise location of transcripts from 483 genes can be found in the open-source spatial genomics dataset known as the Vizgen multiplexed error resilient fluorescence in situ hybridization mouse brain receptor map. Therefore, the above-mentioned factors help the FISH segment to dominate the market.

Geographical Penetration

Rising higher rates of infectious diseases, genetic abnormalities drives the region

North America'sIn Situ Hybridization market is anticipated to grow in the forecast period owing to increasing product launches by the key players in the region. For instance, because to the region's higher rates of infectious diseases, genetic abnormalities, and cancer, North America is anticipated to hold the majority of the market share for in situ hybridization. The market is also anticipated to increase as a result of increasing research and development efforts, the existence of major industry competitors, and regular product debuts. For instance, estimated numbers of new cancer cases and fatalities in 2022, according of the American Cancer Society (In 2022, there will be an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States.). The 2022 year special section examines the prevalence of cancer risk factors and screening among American Indian and Alaska Native (AIAN) people.

Competitive Landscape

The major global players in the market include Abbott Laboratories, F. Hoffmann-La Roche Ag, Becton, Dickinson And Company, Agilent Technologies, Inc, Thermo Fisher Scientific, Bio-Rad Laboratories, Inc, Bio-Techne Corporation, Creative Bioarray, Biocat Gmbh, Zytovision.

COVID-19 Impact Analysis

By Product

  • Consumables
  • Instruments
  • Software

By Technology

  • FISH
    • DNA FISH
    • RNA FISH
    • PNA FISH
  • CISH

By Application

  • Cancer Diagnostics
  • Cytology
  • Infectious Disease Diagnostics
  • Neuroscience
  • Immunology

By End User

  • Hospitals & Diagnostic Laboratories
  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Contract research organizations

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Russia
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In April 6, 2021, A strategic business relationship between Applied Spectral Imaging (ASI) and KromaTiD, Inc. has been announced. Under this partnership, ASI will have the exclusive worldwide rights to offer Pinpoint FISH (PPF) probes and test services developed by KromaTiD.
  • In March 10, 2020, an Improved FISH Probe is Introduced by Creative Bioarray to Identify 2019 New Coronavirus. Viral particles in infected cells can be recognized using in site hybridization (ISH), which also offers precise molecular identification and visualization of infected cell types and regions.
  • On May 26, 2020, The CE-IVD designated RNAscope In Situ Hybridization Detection Kit for automation on the BOND-III platform has been made available in Europe by Leica Biosystems and Bio-Techne. Leica's platform and Bio-RNAscope Techne will give pathologists access to the top applications to help their diagnostics labs.

Why Purchase the Report?

  • To visualize the global In Situ Hybridization- market segmentation based on product, technology, application, end-user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of In Situ Hybridization market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global In Situ Hybridization market report would provide approximately 61 tables, 58 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Application
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing incidence of Cancer cases
      • 4.1.1.2. Awareness about companion diagnostics
      • 4.1.1.3. XX
    • 4.1.2. Restraints
      • 4.1.2.1. Lack of trained personnel will hamper the market
      • 4.1.2.2. XX
    • 4.1.3. Opportunity
      • 4.1.3.1. XX
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Unmet needs
  • 5.6. Pipe line analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. PostCOVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Consumables*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Instruments
  • 7.4. Software

8. By Technology

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. FISH*
    • 8.2.1. DNA FISH
    • 8.2.2. RNA FISH
    • 8.2.3. PNA FISH
    • 8.2.4. Introduction
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. CISH

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), ByApplication
    • 9.1.2. Market Attractiveness Index, By Application
  • 9.2. Cancer Diagnostics*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Cytology
  • 9.4. Infectious Disease Diagnostics
  • 9.5. Neuroscience
  • 9.6. Immunology

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.1.2. Market Attractiveness Index, By Application
  • 10.2. Hospitals & Diagnostic Laboratories*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Academic & Research Institutes
  • 10.4. Pharmaceutical & Biotechnology Companies
  • 10.5. Contract research organizations

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis andY-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis andY-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Russia
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Abbott Laboratories*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. F. Hoffmann-La Roche Ag.
  • 13.3. Becton, Dickinson And Company
  • 13.4. Agilent Technologies, Inc.
  • 13.5. Thermo Fisher Scientific
  • 13.6. Bio-Rad Laboratories, Inc.
  • 13.7. Bio-Techne Corporation
  • 13.8. Creative Bioarray
  • 13.9. Biocat Gmbh
  • 13.10. Zytovision.

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us